sameAs
Lifestyle Modifications and Colorectal CancerCommon germline variants within the CDKN2A/2B region affect risk of pancreatic neuroendocrine tumorsTransforming growth factor beta 1 and metalloproteinase-9 overexpression in colorectal cancer (CC) and adenoma.Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients.Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial.A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery.Biosimilar medicines - their use in the treatment of inflammatory bowel diseases. Position statement of the Working Group of the Polish National Consultant in GastroenterologyCirculating levels of visfatin, resistin and pro-inflammatory cytokine interleukin-8 in acute pancreatitis.Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic PancreatitisSerum adiponectin, resistin, leptin concentration and central adiposity parameters in Barrett's esophagus patients with and without intestinal metaplasia in comparison to healthy controls and patients with GERD.Quality of life in patients with Irritable Bowel Syndrome (IBS), assessed using the IBS-Quality of Life (IBS-QOL) measure after 4 and 8 weeks of treatment with mebeverine hydrochloride or pinaverium bromide: results of an international prospective oIron deficiency anaemia in patients with inflammatory bowel disease: National Consultant for Gastroenterology Working Group RecommendationsThe prevalence of cationic trypsinogen (PRSS1) and serine protease inhibitor, Kazal type 1 (SPINK1) gene mutations in Polish patients with alcoholic and idiopathic chronic pancreatitisRole of cyclooxygenase-2 gene polymorphisms in pancreatic carcinogenesisCommon variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer.New pharmaceuticals in inflammatory bowel diseaseInterleukin 18 as an early marker or prognostic factor in acute pancreatitis.Analysis of XRCC2 and XRCC3 gene polymorphisms in pancreatic cancerPancreatic cyst fluid analysis for differential diagnosis between benign and malignant lesions.Subclinical Inflammation and Endothelial Dysfunction in Patients with Chronic Pancreatitis and Newly Diagnosed Pancreatic Cancer.Liver-intestine-cadherin is a sensitive marker of intestinal differentiation during Barrett's carcinogenesisThe estimation of metaloproteinases and their inhibitors blood levels in patients with pancreatic tumors.The prevalence of celiac disease in patients with irritable bowel syndrome and its subtypes.Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer riskSLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival.Transient receptor potential vanilloid 4 blockade protects against experimental colitis in mice: a new strategy for inflammatory bowel diseases treatment?Clinical, emotional and social factors associated with quality of life in chronic pancreatitis.Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation.Genome-wide association study identifies inversion in the CTRB1-CTRB2 locus to modify risk for alcoholic and non-alcoholic chronic pancreatitis.DNA damage in human colonic mucosa cells evoked by nickel and protective action of quercetin - involvement of free radicals?Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH).Management of acute pancreatitis (AP) - Polish Pancreatic Club recommendations.Clinical value of serum neopterin, tissue polypeptide-specific antigen and CA19-9 levels in differential diagnosis between pancreatic cancer and chronic pancreatitis.Genetic susceptibility to pancreatic cancer and its functional characterisation: the PANcreatic Disease ReseArch (PANDoRA) consortium.Amplification of Her-2/neu oncogene in GERD - Barrett's metaplasia – dysplasia - adenocarcinoma sequence.Role of adipocytokines and its correlation with endocrine pancreatic function in patients with pancreatic cancer.Systemic Administration of Sialorphin Attenuates Experimental Colitis in Mice via Interaction With Mu and Kappa Opioid Receptors.Vitamin C and quercetin modulate DNA-damaging effect of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG).Transient receptor potential vanilloid 4 inhibits mouse colonic motility by activating NO-dependent enteric neurotransmission.FABP4 blocker attenuates colonic hypomotility and modulates white adipose tissue-derived hormone levels in mouse models mimicking constipation-predominant IBS.
P50
Q26865414-1C984634-854D-4F5D-8729-FD47EC35A97EQ28397098-9B787B54-5B6A-4EDB-9B8C-543C60E7F87AQ33280468-C6F34D1A-52A4-48B5-9E7A-93E4DDAE2E3AQ33382136-C28DC549-AA5E-4977-BA3D-AE9D0C53CD27Q33446564-F8DB1984-3F4A-47F6-9E8F-87A4D4D4550DQ33449829-C5ED7C0E-0E86-4557-A69B-13CE110FE5DBQ33636715-551FA9CD-99AE-457E-B20D-3A45CD6812C3Q33663326-5223C821-596F-4CE7-AE95-EA0E45E911C1Q33808976-59C7F6CF-7E55-400D-83EA-CB446AE6CDE5Q34402155-AC297DB0-13FE-4E36-9C2B-5CF306757DC5Q34410818-3E7F43ED-A296-48F3-8EAD-BE5B185D8001Q34466623-E8B28ACE-304C-46AF-8CE7-4BCE667504EBQ34586885-8B818B95-8116-40AF-9A88-C180362F2616Q35465562-A3001926-CAD1-4DEA-88B0-6A4FB87AF59EQ35904497-14C1F6B4-519D-4C26-AD87-9F57F540D681Q36243912-93FE6FDC-AE55-409B-A0BA-14ABC537F124Q36418938-7509EAEF-215A-4AE0-B9B4-4E49C36AE03DQ36524451-156FB88B-AB94-4123-AB3D-1DAFB8885F14Q36611768-05B3C6EF-08DA-4F92-8D70-B55AD8BB2CA6Q36680316-70E1FB0D-6E17-45DC-A496-E02FDB778F13Q36739396-47803FC0-03BE-47C5-B5A9-11D05E458D0FQ36982788-7C76BE68-E16D-47A2-A84B-474945FB2766Q37553658-39AAA99F-1C68-4F15-8E60-EEAA0B749E09Q37636741-A38A009A-0B8D-42AD-B325-2F54E87F9E9DQ37685797-928A585D-EA07-45C2-8D7C-1DDA1CF376CBQ39571226-987237EA-F238-4410-9375-3FFBFC3E1975Q39889360-FE978CF0-718B-4B36-A682-63C8F1DDEAE1Q40039447-B58B7CC8-1D74-4F29-8E37-9D25C57D68A9Q40103441-6C3A9BAC-7C9D-4D05-8126-8E7D70B85603Q40705405-8378FD94-E8E4-4527-B209-8761147B77EFQ42012570-7A4DDDC0-3E1B-4F8A-B109-A9274B31B7E3Q42577708-6C3B5FE9-D102-48A5-9900-6F2D5A1363ABQ42757107-0D3044CB-C097-4C87-A01B-0267F6846181Q43538243-07466E58-D4B8-4DF8-AAC3-993271364749Q43990087-CE12F1E4-7BA3-4F98-BF1E-4C160826E774Q44272390-69B7FBB8-FDFE-4E8F-B793-DC695F8974AEQ44344238-6CB13B57-E640-4D3C-9826-B664D7C8F6F8Q45713265-FEA5E598-14B9-4223-8B4A-FF1579F67A4FQ46800669-3B9E3A86-0ADD-4D70-8164-F3C382F27052Q47265903-FD1EFE32-E2DF-4C4A-86A1-06ABA854E509
P50
description
onderzoeker
@nl
polska lekarka
@pl
researcher ORCID ID = 0000-0002-1825-1807
@en
name
Ewa Malecka-Panas
@en
Ewa Małecka-Panas
@ast
Ewa Małecka-Panas
@ca
Ewa Małecka-Panas
@cs
Ewa Małecka-Panas
@es
Ewa Małecka-Panas
@gl
Ewa Małecka-Panas
@hr
Ewa Małecka-Panas
@hsb
Ewa Małecka-Panas
@it
Ewa Małecka-Panas
@nl
type
label
Ewa Malecka-Panas
@en
Ewa Małecka-Panas
@ast
Ewa Małecka-Panas
@ca
Ewa Małecka-Panas
@cs
Ewa Małecka-Panas
@es
Ewa Małecka-Panas
@gl
Ewa Małecka-Panas
@hr
Ewa Małecka-Panas
@hsb
Ewa Małecka-Panas
@it
Ewa Małecka-Panas
@nl
altLabel
Ewa Izabela Małecka-Panas
@pl
Ewa Małecka-Panas
@en
prefLabel
Ewa Malecka-Panas
@en
Ewa Małecka-Panas
@ast
Ewa Małecka-Panas
@ca
Ewa Małecka-Panas
@cs
Ewa Małecka-Panas
@es
Ewa Małecka-Panas
@gl
Ewa Małecka-Panas
@hr
Ewa Małecka-Panas
@hsb
Ewa Małecka-Panas
@it
Ewa Małecka-Panas
@nl
P214
P106
P1153
35580749200
P1412
P1559
Ewa Malecka-Panas
@pl
P21
P214
P27
P31
P3124
P496
0000-0002-1825-1807
P569
1950-01-01T00:00:00Z
P7859
viaf-165444436